Craft Telemedicine today announced the official launch of its innovative telemedicine platform that eliminates subscription models and empowers patients with unprecedented choice and transparency in their healthcare decisions. Unlike traditional...
Alafair Biosciences, Inc., a leading innovator in medical device technology, is pleased to announce the first patient enrolled at UC Davis Foot and Ankle Orthopaedics Clinic, as part of a prospective, multi-center, controlled case series...
Shed, a modern wellness company focused on helping individuals feel and function their best, announces the launch of several new products designed to provide affordable, weight management support options for individuals at every stage of their...
multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk NMIBC. LEGEND’s pivotal cohort (Cohort 1) consists of approximately 100 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary...
Kashiv BioSciences, LLC announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The randomized, double-blind, multicenter study...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announces it has been named the Fierce CRO Award winner in the Excellence in...
High-Performance Liquid Phase Separations and Related Techniques - Waters Corporation (NYSE: WAT) today announced the release of the Alliance iS HPLC System Software version 2.0, a significant advancement that delivers comprehensive, end-to-end...
SoBran, Inc., a leading provider of bioscience support services, is proud to announce the expansion of its BioScience division into the Los Angeles area. This strategic move aims to bolster the region's vibrant biomedical research community by...
Exobiosphere S.à r.l. and Space Cargo Unlimited today announced the signing of a Memorandum of Understanding (MoU) during the Paris Air Show to launch joint space missions focused on high-throughput biotechnology research. High-throughput...
against oncogenic drivers. The HER family of tyrosine kinases include HER1 (epidermal growth factor receptor [EGFR] or ERBB1), HER2 (HER2/neu or ERBB2), HER3, and HER4. EGFR mutations were one of the first oncogenic drivers that were successfully...
trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE) level-based dosing regimen of Xolair (n=179) every two or four...
Mezzion Pharma Co., Ltd. (Mezzion), a leader in rare disease therapeutics, announced the expansion of its udenafil pipeline with the initiation of a pre-clinical study for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This initiative...
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics...
Samsung Biologics a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are...
all were low grade (1/2) and resolved. One patient had immune effector cell-associated neurotoxicity syndrome (ICANS; grade 1), which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients (58 percent); five (16...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading cell technology company specializing in the generation of predictive human disease models is pleased to announce the launch of its modular iPSCore™ platform. iXCells’ mission is to empower...
Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, which enrolled 173 patients, and TRUST-II (NCT04919811), a global study, which enrolled 164 patients. The primary endpoint of these registrational studies is confirmed objective...
Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced an exclusive agreement with Agios Pharmaceuticals Inc. A...
Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...
CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics,...
